Investing.com -- In a welcome shift from recent AI doom reports, Novo Nordisk announced a major collaboration with Anthropic on Wednesday—highlighting artificial intelligence’s immense potential to save lives rather than threaten them.

The partnership will pair Anthropic’s frontier models with Novo’s world-class scientists to tackle complex drug discovery challenges, streamline biological reasoning, and transform R&D workflows.

Novo Nordisk will use Anthropic’s models and Claude Science to advance scientific reasoning in research and development, as well as for agentic software engineering. The company will initially test Claude Science for specific R&D workflows and scientific problems where the combined capabilities of both companies are expected to have the greatest impact.

"This partnership is another testament to our ambition to become the world’s most AI-driven healthcare company, building on Novo’s current AI initiatives with other technology partners," said Mike Doustdar, president and CEO of Novo Nordisk. "AI can help us increase productivity in R&D and compress the path from research to marketed product."

Dario Amodei, co-founder and CEO of Anthropic, said the collaboration aims to shorten research timelines and improve outcomes.

Novo Nordisk will also use Anthropic’s frontier models to strengthen AI-driven software development across the company. The collaboration includes data governance and human oversight measures designed to align with Novo’s ethical and compliance standards.